Related Experiment Videos
17beta-estradiol prevents programmed cell death in cardiac myocytes
T Pelzer1, M Schumann, M Neumann
1Department of Medicine, University of Würzburg, Würzburg, D-97080, Germany.
Biochemical and Biophysical Research Communications
|February 1, 2000
Summary
Physiological doses of 17beta-estradiol prevent cardiac myocyte apoptosis, a key factor in heart failure. This estrogen effect, mediated by reduced caspase-3 and NF-kappaB activity, offers new therapeutic avenues.
Area of Science:
- Cardiovascular Science
- Endocrinology
- Cell Biology
Background:
- Estrogens are known for cardioprotective effects, but the mechanisms remain unclear.
- Programmed cell death (apoptosis) contributes to cardiac myocyte loss in heart failure.
- Estrogens inhibit apoptosis in other cell types, like breast cancer cells.
Purpose of the Study:
- To investigate if 17beta-estradiol prevents apoptosis in cardiac myocytes.
- To explore the underlying molecular mechanisms of estrogen's potential antiapoptotic effects in the heart.
Main Methods:
- Cardiac myocytes were cultured and apoptosis was induced using staurosporine.
- The effects of 17beta-estradiol (10 nM) on apoptosis were assessed via morphological analysis, Hoechst 33342 staining, and TUNEL assay.
- Activity of caspase-3 and NF-kappaB transcription factors (p65/RelA, p50) was measured.
Main Results:
- 17beta-estradiol demonstrated a significant antiapoptotic effect on cultured cardiac myocytes.
- This protective effect was associated with reduced activity of the protease caspase-3.
- Estradiol treatment also led to decreased activity of NF-kappaB transcription factors, including p65/RelA and p50.
Conclusions:
- 17beta-estradiol at physiological concentrations inhibits apoptosis in cardiac myocytes.
- The antiapoptotic action of estrogens in the heart may contribute to their known cardioprotective properties.
- These findings suggest potential for developing novel therapeutic strategies targeting estrogen pathways for heart conditions.